title: Serum lipid variations in women on copper intrauterine devices, triphasic oral contraceptives and monthly injectable contraceptives.
abstract: This is a longitudinal, prospective, comparative controlled study. Patient selection excluded smokers, overweighed, hypertensive, and aged greater than 34 years. 168 women were distributed by random list into four groups: A) fitted with inert IUD (control); B) with Nova T (Cu-IUD); C) received triphasic gestodene (OC); and D) monthly norethisterone enanthate 50 mg + estradiol valerate 5 mg (injectable). Serum lipid patterns were assessed at the beginning of contraceptive use and at 1, 6 and 12 months. The results of the Cu-IUD group did not show any difference with the control group. The OC group showed an increase of HDL and a significant lowering of LDL cholesterol at 6 months but this reverted by 12 months. On the other hand, in the injectable group, a sharp decrease of total lipids, total cholesterol and LDL was observed from the first month, lasting throughout 12 months, yielding significant difference with controls and also with pre-treatment values. In sum, the monthly injectable showed quite favorable patterns that would deserve further study, especially in view of the scarcity of hitherto available information concerning this formulation.
authors.affiliation: 1st Gynaecological Clinic, University of Buenos Aires, Argentina.
authors.forename: E
authors.initials: E
authors.lastname: Kesserü
authors.forename: H
authors.initials: H
authors.lastname: Albornoz
authors.forename: M
authors.initials: M
authors.lastname: Díaz
authors.forename: R
authors.initials: R
authors.lastname: Socolsky
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003276:Contraceptives, Oral / Q000494:pharmacology*; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007435:Intrauterine Devices, Copper; D008055:Lipids / Q000097:blood*; D008137:Longitudinal Studies; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009652:Norpregnenes / Q000494:pharmacology*; D011446:Prospective Studies; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003276:Contraceptives, Oral; D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D009652:Norpregnenes; D014280:Triglycerides; C033273:Gestodene; D004958:Estradiol; C024319:norethindrone enanthate; D009640:Norethindrone